intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.disopyramideSerious - Use Alternative (1)escitalopram increases toxicity of disopyramide by QTc interval. Avoid or Use Alternate Drug.dofetilideSerious - Use Alternative (2)dofetilide increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug. escitalopram increases toxicity of dofetilide by QTc interval. Avoid or Use Alternate Drug.dolasetronMonitor Closely (2)dolasetron, escitalopram. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor ECG, symptoms of serotonin syndrome especially during initiation/titration. escitalopram increases toxicity of dolasetron by QTc interval. Use Caution/Monitor.donepezilMonitor Closely (1)donepezil and escitalopram both increase QTc interval. Use Caution/Monitor.dosulepinSerious - Use Alternative (1)escitalopram and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.doxepinSerious - Use Alternative (2)escitalopram and doxepin both increase serotonin levels. Avoid or Use Alternate Drug. doxepin and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.dronedaroneContraindicated (1)escitalopram increases toxicity of dronedarone by QTc interval. Contraindicated.droperidolSerious - Use Alternative (1)escitalopram increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug.duloxetineMonitor Closely (1)duloxetine and escitalopram both increase serotonin levels. Use Caution/Monitor.duvelisibMonitor Closely (1)duvelisib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.edoxabanMonitor Closely (1)escitalopram increases effects of edoxaban by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.efavirenzMonitor Closely (3)efavirenz will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. efavirenz will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. efavirenz and escitalopram both increase QTc interval. Use Caution/Monitor.elagolixMonitor Closely (2)elagolix will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates. elagolix will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eletriptanMonitor Closely (1)eletriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (1)escitalopram, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.eliglustatMonitor Closely (1)eliglustat and escitalopram both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibMonitor Closely (1)encorafenib, escitalopram. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.Serious - Use Alternative (1)escitalopram increases toxicity of encorafenib by QTc interval. Avoid or Use Alternate Drug.entrectinibSerious - Use Alternative (1)escitalopram and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.enzalutamideSerious - Use Alternative (1)enzalutamide will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ergotamineMonitor Closely (1)escitalopram and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.eribulinSerious - Use Alternative (1)escitalopram increases toxicity of eribulin by QTc interval. Avoid or Use Alternate Drug.erythromycin baseSerious - Use Alternative (1)escitalopram increases toxicity of erythromycin base by QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateSerious - Use Alternative (1)escitalopram increases toxicity of erythromycin ethylsuccinate by QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateSerious - Use Alternative (1)escitalopram increases toxicity of erythromycin lactobionate by QTc interval. Avoid or Use Alternate Drug.erythromycin stearateSerious - Use Alternative (1)escitalopram increases toxicity of erythromycin stearate by QTc interval. Avoid or Use Alternate Drug.eslicarbazepine acetateMonitor Closely (1)eslicarbazepine acetate will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.esmololMinor (1)escitalopram increases levels of esmolol by decreasing metabolism. Minor/Significance Unknown.esomeprazoleMonitor Closely (1)esomeprazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.ethacrynic acidMinor (1)ethacrynic acid, escitalopram. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.etodolacMonitor Closely (1)escitalopram, etodolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.etravirineMonitor Closely (2)etravirine will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. etravirine will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ezogabineMonitor Closely (2)escitalopram increases toxicity of ezogabine by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed, particularly when dose titrated to 1200mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval. ezogabine, escitalopram. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibMonitor Closely (2)fedratinib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary. fedratinib will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.felbamateMonitor Closely (1)felbamate will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.felodipineMinor (1)felodipine will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.fenbufenMonitor Closely (1)escitalopram, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fenfluramineMonitor Closely (2)fenfluramine, escitalopram. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. escitalopram and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenoprofenMonitor Closely (1)escitalopram, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fentanylSerious - Use Alternative (1)fentanyl, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl intranasalSerious - Use Alternative (1)fentanyl intranasal, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transdermalSerious - Use Alternative (1)fentanyl transdermal, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transmucosalSerious - Use Alternative (1)fentanyl transmucosal, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fexinidazoleMonitor Closely (1)fexinidazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.Serious - Use Alternative (2)fexinidazole and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval. fexinidazole will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates. fingolimodMonitor Closely (1)fingolimod and escitalopram both increase QTc interval. Use Caution/Monitor.fish oil triglyceridesMonitor Closely (1)fish oil triglycerides will increase the level or effect of escitalopram by anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants.flecainideSerious - Use Alternative (1)escitalopram increases toxicity of flecainide by QTc interval. Avoid or Use Alternate Drug.fluconazoleMonitor Closely (2)fluconazole will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. escitalopram increases toxicity of fluconazole by QTc interval. Use Caution/Monitor.fluoxetineMonitor Closely (1)escitalopram and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (2)escitalopram and fluoxetine both increase serotonin levels. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug.fluphenazineMonitor Closely (1)escitalopram increases toxicity of fluphenazine by QTc interval. Use Caution/Monitor.flurbiprofenMonitor Closely (1)escitalopram, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.fluvoxamineSerious - Use Alternative (1)fluvoxamine and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug.fondaparinuxMonitor Closely (1)escitalopram increases effects of fondaparinux by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.formoterolMonitor Closely (1)escitalopram increases toxicity of formoterol by QTc interval. Use Caution/Monitor.fosamprenavirMonitor Closely (1)fosamprenavir increases levels of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of serotonin syndrome.foscarnetSerious - Use Alternative (1)escitalopram increases toxicity of foscarnet by QTc interval. Avoid or Use Alternate Drug.fosphenytoinMonitor Closely (1)fosphenytoin will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fostemsavirMonitor Closely (1)escitalopram and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. frovatriptanMonitor Closely (1)frovatriptan and escitalopram both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (1)escitalopram, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.furosemideMinor (1)furosemide, escitalopram. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.gabapentinMonitor Closely (1)gabapentin, escitalopram. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilMonitor Closely (1)gabapentin enacarbil, escitalopram. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gadobenateMonitor Closely (1)gadobenate and escitalopram both increase QTc interval. Use Caution/Monitor.ganaxoloneMonitor Closely (1)escitalopram and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinMonitor Closely (1)escitalopram increases toxicity of gemifloxacin by QTc interval. Use Caution/Monitor.gemtuzumabMonitor Closely (1)escitalopram increases toxicity of gemtuzumab by QTc interval. Use Caution/Monitor.gilteritinibSerious - Use Alternative (2)gilteritinib will decrease the level or effect of escitalopram by Other (see comment). Avoid or Use Alternate Drug. Coadministration of gilteritinib with drugs that inhibit 5HT2B or sigma nonspecific receptors. Avoid use of these drugs with gilteritinib unless coadministration is necessary. gilteritinib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.glasdegibSerious - Use Alternative (1)escitalopram and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.goserelinContraindicated (1)goserelin increases toxicity of escitalopram by QTc interval. Contraindicated. Increases risk of torsades de pointes.granisetronMonitor Closely (1)granisetron and escitalopram both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)granisetron, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.green teaMonitor Closely (1)green tea, escitalopram. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of bleeding.haloperidolMonitor Closely (2)escitalopram increases toxicity of haloperidol by QTc interval. Use Caution/Monitor. haloperidol and escitalopram both increase QTc interval. Use Caution/Monitor.histrelinSerious - Use Alternative (1)histrelin increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.hydrocodoneMonitor Closely (1)hydrocodone, escitalopram. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydromorphoneSerious - Use Alternative (1)hydromorphone, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.hydroxychloroquine sulfateSerious - Use Alternative (2)hydroxychloroquine sulfate and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. escitalopram increases toxicity of hydroxychloroquine sulfate by QTc interval. Avoid or Use Alternate Drug.hydroxyureaMonitor Closely (1)escitalopram, hydroxyurea. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of myelosuppression.hydroxyzineMonitor Closely (1)hydroxyzine and escitalopram both increase QTc interval. Use Caution/Monitor.ibrutinibMonitor Closely (1)ibrutinib will increase the level or effect of escitalopram by anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding. ibuprofenMonitor Closely (1)escitalopram, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ibuprofen IVMonitor Closely (1)escitalopram, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ibutilideSerious - Use Alternative (1)escitalopram increases toxicity of ibutilide by QTc interval. Avoid or